Columbus Venture Partners, a leading Spanish venture capital firm specializing in the life sciences sector, has officially announced the closing of its fifth fund: Columbus Innvierte Life Sciences Fund V. With a target size of €200 million and regulatory flexibility allowing it to reach up to €220 million, the vehicle is formally established as the largest biotechnology fund in the firm’s historical track record
This new fund stands out not only for its financial scale, but also for representing the culmination of a strategic vision focused on fundamentally transforming healthcare and medicine in Europe. In the words of Javier García and Damià Tormo, General Partners at Columbus Venture Partners: “This new fund is, in addition to being the most ambitious biotech investment in our country, the culmination of a strategy we have been developing since our inception, combining investment in high-impact science with the creation of industrial and technological capabilities that allow that science to reach patients faster and better”
Three strategic transformation pillars
The vehicle has been explicitly designed to support and drive the next generation of companies within the biotech and healthtech verticals. Its investment thesis responds to three major global challenges and structural transformations:
Regarding this strategic deployment within the current environment, Julen Oyarzabal, Partner at the firm, highlights: “The fund’s strategy responds to the growing need to strengthen industrial and technological capabilities within the healthcare sector, in a context marked by scientific acceleration, regulatory complexity, and the need to reduce development timelines”
Investment criteria and capital deployment
Columbus Innvierte Life Sciences Fund V will primarily focus its resources on technology companies at Series A stage and beyond, taking a leading role in financing rounds (p. 5). However, it will retain the flexibility to take agile positions in exceptional early-stage opportunities
Jose Mesa, Partner at Columbus Venture Partners, details the financial structure of the operations: “The fund will invest in companies from Series A onwards, maintaining flexibility to participate in exceptional opportunities at any stage, with an expected average investment ticket of €15 million”
This €15 million average ticket will include both initial equity investment and follow-on commitments in subsequent funding rounds.
First investments already underway
The strategic vision of this fifth fund has already materialised through the successful execution of its first three portfolio investments, demonstrating the manager’s ability for immediate deployment:
With this launch, Columbus Venture Partners, founded in 2016, significantly expands its assets under management and reaffirms its position as one of the most influential and effective life sciences venture capital players in Southern Europe.
About Columbus Venture Partners
Columbus Venture Partners SGEIC, S.A. is a Spanish venture capital management company founded in 2016 by Javier García and Damià Tormo. Specialised in biotechnology, life sciences, and health technologies, it stands out in the market for a unique operating model that combines pharmaceutical development investment with the direct creation of production capabilities and industrial platforms for advanced therapies.
cloud technology axon
This new fund is, in addition to being the most ambitious biotech inve...
